Enliven Therapeutics, Inc. (ELVN)
Total Valuation
ELVN has a market cap or net worth of $886.02 million. The enterprise value is $593.87 million.
| Market Cap | 886.02M |
| Enterprise Value | 593.87M |
Important Dates
The next estimated earnings date is Wednesday, August 2, 2023, before market open.
| Earnings Date | Aug 2, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
ELVN has 41.11 million shares outstanding. The number of shares has increased by 543.59% in one year.
| Shares Outstanding | 41.11M |
| Shares Change (YoY) | +543.59% |
| Shares Change (QoQ) | +177.58% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
The trailing PE ratio is 13.14.
| PE Ratio | 13.14 |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.04 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 423.28 |
| EV / Sales | n/a |
| EV / EBITDA | 278.42 |
| EV / EBIT | 398.30 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 27.24
| Current Ratio | 27.24 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is 1.10% and return on invested capital (ROIC) is 14.60%.
| Return on Equity (ROE) | 1.10% |
| Return on Assets (ROA) | 1.10% |
| Return on Capital (ROIC) | 14.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ELVN has paid $88,000 in taxes.
| Income Tax | 88,000 |
| Effective Tax Rate | 5.90% |
Stock Price Statistics
The stock price has increased by +374.29% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | +374.29% |
| 50-Day Moving Average | 20.26 |
| 200-Day Moving Average | 16.65 |
| Average Volume (30 Days) | 132,869 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.03M |
| Pretax Income | 1.49M |
| Net Income | 1.40M |
| EBITDA | 2.13M |
| EBIT | 1.49M |
| Earnings Per Share (EPS) | $1.64 |
Balance Sheet
| Cash & Cash Equivalents | 292.16M |
| Total Debt | n/a |
| Net Cash | 292.16M |
| Net Cash Per Share | $7.11 |
| Equity / Book Value | 291.42M |
| Book Value Per Share | 7.09 |
| Working Capital | 287.06M |
Cash Flow
In the last 12 months, operating cash flow was -$39.25 million and capital expenditures -$259,000, giving a free cash flow of -$39.51 million.
| Operating Cash Flow | -39.25M |
| Capital Expenditures | -259,000 |
| Free Cash Flow | -39.51M |
| FCF Per Share | -$2.13 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ELVN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | 0.16% |
| FCF Yield | -4.46% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -543.59% |
| Shareholder Yield | -543.59% |
Analyst Forecast
The average price target for ELVN is $27.00, which is 25.29% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $27.00 |
| Price Target Difference | 25.29% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |